United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - methotrexate - oral tablet - 2.5mg

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - methotrexate 2.5mg;   - tablet - 2.5 mg - active: methotrexate 2.5mg   excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose polysorbate 80 starch - for the treatment of breast cancer

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - methotrexate - tablet - 2.500 mg - methotrexate 2.500 mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

orion corporation / orion pharma - methotrexate - tablets - 2,5mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

orion corporation / orion pharma - methotrexate - tablets - 2,5mg

Canada - English - Health Canada

accord healthcare inc - methotrexate (methotrexate disodium) - tablet - 2.5mg - methotrexate (methotrexate disodium) 2.5mg - antineoplastic agents

Canada - English - Health Canada

auro pharma inc - methotrexate (methotrexate disodium) - tablet - 2.5mg - methotrexate (methotrexate disodium) 2.5mg

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - methotrexate - tablets - methotrexate 2.5 mg - methotrexate - methotrexate - antineoplastic chemotherapy, psoriasis. rheumatoid arthritis. methotrexate can be used in the treatment of selected adults with rheumatoid arthritis, only when the diagnosis has been well established according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - methotrexate 100 mg/ml - concentrate for injection - 100 mg/ml - active: methotrexate 100 mg/ml excipient: sodium hydroxide water for injection - antineoplastic chemotherapy. methotrexate has a broad spectrum of antineoplastic activity. it is indicated for the treatment of breast cancer and the palliation of acute and subacute lymphocytic leukaemia (greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias). methotrexate is now most commonly used for the maintenance of medicine induced remissions. high dose therapy. in high dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic carcinoma. calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy. psoriasis chemotherapy. methotrexate may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatological consultation.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - methotrexate sodium (unii: 3ig1e710zn) (methotrexate - unii:yl5fz2y5u1) - methotrexate 25 mg in 1 ml - methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. in acute lymphocytic leukemia, methotrexate is indicated for use in maintenance therapy in combination with other chemotherapeutic agents.   methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous t cell lymphoma), and lung cancer, particularly squamous cell and small cell types. methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-hodgkin’s lymphomas. methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. methotrexate is indicated in the symptomatic control of se